AbbVie News Center - News
News Abb Vie. Copyright © 2017 AbbVie Inc. North Chicago, Illinois, U.S.A....
Read News.abbvie.com news digest here: view the latest News Abb Vie articles and content updates right away or get to their most visited pages. News.abbvie.com is not yet rated by Alexa. It seems that News Abb Vie content is notably popular in USA, as 48.7% of all users (14K visits per month) come from this country. We haven’t detected security issues or inappropriate content on News.abbvie.com and thus you can safely use it. News.abbvie.com is hosted with CloudFlare, Inc. (United States) and its basic language is English.
Content verdict: Safe
Website availability: Live
Language: English
Last check:
-
936
Visitors daily -
2 715
Pageviews daily -
N/A
Google PR -
N/A
Alexa rank
Best pages on News.abbvie.com
-
AbbVie Inc. Newsroom - the official site for press releases, photos, video, audio, pr contact information, presskits and more.
-
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in...
-
Collaboration to leverage BigHat's Artificial Intelligence and Machine Learning (AI/ML) guided Milliner™ platform and AbbVie's expertise in Oncology and Neuroscience to develop next-generation...
-
Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant...
News.abbvie.com news digest
-
5 months
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strength...
Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage...
-
5 months
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artifi...
Collaboration to leverage BigHat's Artificial Intelligence and Machine Learning (AI/ML) guided Milliner™ platform and AbbVie's expertise in Oncology and Neuroscience to develop next-generation...
-
5 months
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mir...
Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant...
-
5 months
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluati...
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in...
Domain history
| Web host: | CloudFlare, Inc. |
| Registrar: | MarkMonitor Inc. |
| Registrant: | Domain Administrator (AbbVie Inc.) |
| Updated: | January 27, 2024 |
| Expires: | February 28, 2025 |
| Created: | February 28, 2012 |
Whois record
Safety scores
Trustworthiness
GoodChild safety
N/A
